Oxycodone hydrochloride sustained-release tablets from a subsidiary company of Zhongguancun (000931.SZ) obtained a drug registration certificate

Zhitong Finance App News, Zhongguancun (000931.SZ) issued an announcement. Recently, Beijing Huasu Pharmaceutical Co., Ltd. (Beijing Huasu), a subsidiary of the company, received the “Drug Registration Certificate” approved and issued by the State Drug Administration and learned that the “oxycodone hydrochloride sustained-release tablets” (specification: 40mg) developed by Beijing Huasu have passed the drug registration review and approval.

According to reports, oxycodone hydrochloride extended-release tablets are clinically used to treat pain that is severe enough to be continued for a long period of time, treated with opioids on time every day, and that cannot be adequately relieved by alternative treatment. Oxycodone hydrochloride is a pure opioid receptor agonist. It is relatively selective for μ-receptors and can also bind to other opioid receptors at higher doses; the main therapeutic effect of oxycodone is analgesia.